Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:SMSPHARMA

SMS PHARMACEUTICALS LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹467.45
at close · 21 Sept 2026
▲ 25.40 (+5.75%)

Latest filings

  1. Intimation of Analyst/Investor Meeting on 15 September 2026 · Board & Shareholder Meetings
  2. Newspaper publication copy submitted to exchange · Compliance
  3. Annual Report Letter Dispatched to Shareholders; 38th AGM on 29 Sep 2026 · Compliance
  4. SMS Pharma files FY26 Business Responsibility and Sustainability Report · Compliance
  5. 38th AGM on 29 Sep 2026; dividend record date 22 Sep · Board & Shareholder Meetings
  6. FY2025-26 annual report and 38th AGM notice · Board & Shareholder Meetings
  7. CARE reaffirms SMS Pharma ratings; outlook cut from Positive to Stable · Credit & Debt
  8. Newspaper publication copy filed with exchange · Compliance
  9. Dividend record date revised to 22nd September 2026 · Corporate Actions
  10. 38th AGM date shifted to 29 September 2026 · Board & Shareholder Meetings
  11. Newspaper notice issued for 38th AGM via video conferencing · Compliance
  12. TDS rules on final dividend of Rs 0.40 per share for FY26 · Corporate Actions
  13. Newspaper publication of Q1 FY27 financial results · Compliance
  14. SMS Pharma Q1FY27 Investor Presentation filed with exchanges · Investor Communications
  15. SMS Pharma Q1FY27 results: Revenue up 6%, PAT up 8%, EBITDA margin at 20% · Compliance
  16. SMS Pharma Q1 PAT up 16% YoY at Rs 21.13 cr; Rs 50 cr loan to subsidiary · Results
  17. Q1 FY27 Results, Record Date 16 Sept for Dividend, Rs 50 Cr Loan to Subsidiary · Results
  18. SMS Pharma Q1 PAT up 16%, MD re-appointed, Rs 50 Cr loan to subsidiary · Management Changes
  19. Q1 FY27: Revenue Rs 207 cr, PAT Rs 21 cr; CMD re-appointed, Rs 50 cr loan to subsidiary · Results
  20. Q1 FY27 results, Rs 50 Cr loan to subsidiary, MD re-appointment · Results
  21. Board meeting preponed from Aug 1 to Jul 31, 2026 · Results
  22. Board meeting on 1 Aug 2026 to approve Q1 FY27 financial results · Results
  23. SMS Pharma notifies shareholders of IEPF share transfer · Compliance
  24. Reminder for transfer of unclaimed dividend shares to IEPF · Compliance
  25. Police arrest in SMS Pharma share impersonation case · Regulatory & Legal
  26. Routine RTA compliance certificate for Q1 FY27 filed with exchanges · Compliance
  27. Routine compliance certificate for Q1 FY27 dematerialization · Compliance
  28. Clarification on spurt in trading volume · Regulatory & Legal
  29. NSE seeks clarification on unusual volume in SMS Pharma · Regulatory & Legal
  30. Trading window closed from July 1 ahead of Q1 results · Compliance
  31. Trading Window Closure for Q1 FY26 Results · Compliance
  32. No new share pledges by promoters in FY26 · Compliance
  33. SMS Pharmaceuticals Limited has informed the Exchange about General Updates · General
  34. Transcripts of the Conference call held on 27th May, 2026 · Investor Communications
  35. SMS Pharmaceuticals Limited has informed the Exchange about Transcript · Investor Communications
  36. Audio recording of Analysts/Investors Conference Call pertaining to the Financial Results for the fourth quarter and year ended 31st March, 2026 · Investor Communications
  37. SMS Pharmaceuticals Limited has informed the Exchange about Link of Recording · Investor Communications
  38. SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
  39. copy of newspaper publication · Compliance
  40. SMS Pharmaceuticals Limited has informed the Exchange about General Updates · Investor Communications
  41. Investor Presentation · Investor Communications
  42. Press Release on Financial Results for the year ended 31.03.2026 · Business Updates
  43. SMS Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 23, 2026, titled "Press Release". · Results
  44. Intimation of Investor Call · Results
  45. SMS Pharmaceuticals Limited has informed the Exchange about Schedule of meet · General
  46. Please find the enclosure · Results
  47. SMS Pharmaceuticals Limited has informed the Exchange regarding change in Registered Office of the company. · General
  48. SMS Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · Results
  49. Please find the enclosure · Results
  50. Re-appointment of Auditors of the Company · Management Changes
All filings ↓
Ask Nexa about SMS PHARMACEUTICALS LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures active pharmaceutical ingredients (APIs) — the bulk drug substances used by generic drug makers — across therapeutic areas including anti-inflammatory (ibuprofen is a major product), anti-retroviral (ARV), anti-erectile dysfunction, and anti-diabetic (the last is being wound down). Backward integration into ibuprofen raw materials, built over three years, is the main margin lever; FY26 EBITDA margin reached 20% on revenue of INR886.87 crore with materials at 58.2% of revenue. A brownfield expansion is under way, intended to add new capacity by March 2027 and bring new high-margin APIs on stream from FY28. The company files DMFs and CEPs to access regulated export markets and is shifting its mix toward higher-value APIs over time. A new peptides subsidiary (SMS Peptides) and a CDMO initiative are medium-term options, not yet material to revenue. Customer base is concentrated: the single largest customer accounts for 28% of FY26 revenue.

Operating scale
Installed API capacity
500 MT/month, expanding to 800 MT/monthby March FY27
Brownfield capex
INR280 cr (INR130 cr deployed)FY26-FY27
DMF/CEP filings
12 in FY26; targeting 10 in FY27 and 10 in FY28FY26-FY28
High-value product share
~47%, target ~60%FY26, medium term
Customer concentration
Single largest customer at 28% of revenueFY26
Associate income
INR14 cr from 34%-owned VKT PharmaFY26
Who pays it
Generic pharmaceutical formulators globally; single largest customer at 28% of FY26 revenue across multiple products
Biggest cost
Raw materials at 58.2% of revenue (materials, including API intermediates; key inflation risk from Middle East geopolitics)
Kind of business
Asset-heavy API manufacturer with multi-therapy exposure, backward integration into key starting materials, and regulated-market filings
Where it sits
Indian API maker filing DMFs/CEPs for regulated export markets; structural margin lever is backward integration in a fragmented domestic API industry
Market Cap
₹4,378 Cr
P / E (TTM)
41.6×
EV / EBITDA
25.8×
Div Yield
0.08%
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
13.2%▲
ROCE (5y median)
ROE 10.8% · margin 20.3%
Leverage
0.46·
Debt / Equity · low
Net debt ₹319 Cr
Revenue FY20→FY26
2.2×▲
Margin +3.6 pts
₹412 Cr → ₹887 Cr
Cash conversion
0.92×·
Operating cash ÷ profit · 5 yrs
₹254 Cr on ₹276 Cr
Moves on a normal day
1.32%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#115/170
P/B#122/164
ROCE#84/183
ROE#59/171
Debt / Equity#138/171
EBITDA margin#71/165
Revenue growth#110/161
Profit growth#106/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Carries more debt than its peers — 0.46× equity
lower than 19% of its 171 Pharmaceuticals peers
Heavy working capital — 184 days of cash tied up
Customers are taking longer to pay — 43 → 89 days of receivables
FY20 → FY26

Charts

How has the market priced it — with filings on the timeline?

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SMS PHARMACEUTICALS LTD.'s filed financials and exchange disclosures

What does SMS PHARMACEUTICALS LTD. do?

SMS PHARMACEUTICALS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SMSPHARMA.

Is SMS PHARMACEUTICALS LTD. profitable?

Yes. Over the trailing twelve months SMS PHARMACEUTICALS LTD. reported a net profit of ₹102 Cr on revenue of ₹898 Cr.

Does SMS PHARMACEUTICALS LTD. pay a dividend?

Yes. The dividend yield is 0.08% at the current price. It paid out 4% of its profit as dividend in FY26.

Is SMS PHARMACEUTICALS LTD. debt-free?

No. Debt stands at 0.46× equity, and it carries net debt of ₹319 Cr. That is lower than 19% of its 171 Pharmaceuticals peers.

Is SMS PHARMACEUTICALS LTD. expensive compared with its peers?

On trailing P/E, SMS PHARMACEUTICALS LTD. ranks 115 of 170 in Pharmaceuticals — cheaper than 33% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the SMS PHARMACEUTICALS LTD. share price move in a day?

On a typical session SMS PHARMACEUTICALS LTD. moves 1.32% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track SMS PHARMACEUTICALS LTD.'s announcements?

Every NSE and BSE filing by SMS PHARMACEUTICALS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.